Calibra Medical gains further Finesse clearance
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for the Finesse insulin patch-pen for up to three-day use with Novo Nordisk's Novolog rapid-acting insulin. Developed by Calibra Medical, Finesse is a small, adhesively attached, flat device that can be operated through clothing to deliver bolus insulin doses. It has already gained FDA clearance for use with Eli Lilly's Humalog fast-acting insulin, and Calibra is pursuing further clearances for Finesse to deliver other manufacturers' insulin and diabetes drugs. It is also planning to develop next-generation models, including devices pre-filled with insulin.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.